Capsule comprising moguisteine

A technology of capsules and micropowdered silica gel, which is applied in capsule delivery, respiratory diseases, drug combinations, etc., and can solve problems such as ineffectiveness, heavy bitterness, and uncontrollable conditions

Inactive Publication Date: 2011-03-09
北京德众万全医药科技有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, β-cyclodextrin inclusion and solid dispersion technology are mostly used to mask the taste, but the conditions are not easy to control, and the final product must be verified by special means, and the process is complicated
The method of adding flavoring agents in the composition does not play a big role when some raw materials have a strong bitter taste

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Capsule comprising moguisteine
  • Capsule comprising moguisteine
  • Capsule comprising moguisteine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018]

[0019] Preparation Process:

[0020] Mogistein passed through a 100-mesh sieve, lactose, calcium hydrogen phosphate and sodium starch glycolate were respectively passed through a 80-mesh sieve, mogistein and lactose were mixed evenly, and then mixed with calcium hydrogen phosphate and sodium starch glycolate to obtain mixture I. Add an appropriate amount of purified water to mixture I to make soft materials, pass through a 20-mesh sieve to make wet granules, air-dry at 50±5°C, pass through a 24-mesh sieve for granulation, mix with micronized silica gel, and fill capsules with a capacity of about 250mg.

Embodiment 2

[0022]

[0023] Preparation Process:

[0024] Mogistein is passed through a 100-mesh sieve, lactose, calcium hydrogen phosphate and sodium starch glycolate are respectively passed through a 80-mesh sieve, mogistein and lactose are mixed evenly, and then mixed with calcium hydrogen phosphate and sodium starch glycolate to obtain mixture I , the mixture I is mixed with micro-powdered silica gel, or after dry granulation, then added with micro-powdered silica gel, mixed evenly, and filled into capsules with a loading capacity of about 250 mg.

Embodiment 3

[0026]

[0027] Preparation Process:

[0028] Mix mogisteine ​​and lactose evenly, pulverize and pass through an 80-mesh sieve to obtain mixture I. Calcium hydrogen phosphate and sodium starch glycolate were passed through a 80-mesh sieve respectively, added to mixture I and mixed evenly to obtain mixture II. The mixture II is mixed with micropowder silica gel, or mixed with micropowder silica gel after dry granulation, and filled into capsules with a loading capacity of about 250mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a Moggi Stan capsules, its characteristics are: mixing Moggi Stan and hydrophilic substances, disintegrating or abrading together, then mixing them with other excipients, filling capsules after preparing tablets with whole powder method or dry method. It has effects of moisture proof, avoiding light and so on, and can conceal adverse tastes of drug, but also avoids the maindrug melting in wet method preparing tablets heating process, while ensures rapid drug absorption and dissolution.

Description

technical field [0001] The invention relates to a non-narcotic antitussive medicine, in particular to a capsule preparation with mogisteine ​​as an active substance. technical background [0002] Antitussives are mainly divided into two categories: central and peripheral. Mogisteine ​​is a peripheral non-narcotic antitussive drug. The clinical effect is similar to that of codeine. Unlike codeine, mogisteine ​​does not act on opioid receptors, but through peripheral receptors, does not cause addiction, and mogisteine ​​has sedative and reduced obligatory spasm responses effect, its higher doses are better tolerated and can be administered to children. [0003] The melting point of mogisteine ​​is about 60°C, and it is easy to cause the main drug to melt during the drying process using the conventional wet granulation process. Mogistein has low solubility in water, which easily leads to low bioavailability of the prepared oral solid preparation. Mogisteine ​​has a severe b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/425A61K9/48A61P11/14
Inventor 晋运环宁美英
Owner 北京德众万全医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap